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ABSTRACT
Objectives: Point-of-care (POC) C reactive protein
(CRP) is incorporated in National Institute of Health
and Care Excellence (NICE) guidelines for the
diagnosis of pneumonia, reduces antibiotic prescribing
and is cost effective.
Aim: To determine the barriers and facilitators to
adoption of POC CRP testing in National Health Service
(NHS) primary care for the diagnosis of lower
respiratory tract infection.
Design: The study followed a qualitative methodology
based on grounded theory. The study was undertaken
in 2 stages. Stage 1 consisted of semistructured
interviews with 8 clinicians from Europe and the UK
who use the test in routine practice, and focused on
their subjective experience in the challenges of
implementing POC CRP testing. Stage 2 was a
multidisciplinary-facilitated workshop with NHS
stakeholders to discuss barriers to adoption, impact of
adoption and potential adoption scenarios. Emergent
theme analysis was undertaken.
Participants: Participants included general
practitioners (including those with commissioning
experience), biochemists, pharmacists, clinical
laboratory scientists and industry representatives from
the UK and abroad.
Results: Barriers to the implementation of POC CRP
exist, but successful adoption has been demonstrated
abroad. Analysis highlighted 7 themes: reimbursement
and incentivisation, quality control and training,
laboratory services, practitioner attitudes and
experiences, effects on clinic flow and workload, use in
pharmacy and gaps in evidence.
Conclusions: Successful adoption models from the
UK and abroad demonstrate a distinctive pattern and
involve collaboration with central laboratory services.
Incorporating antimicrobial stewardship into quality
improvement frameworks may incentivise adoption.
Further research is needed to develop scaling-up
strategies to address the resourcing, clinical
governance and economic impact of widespread NHS
implementation.
INTRODUCTION
The majority of patients presenting to
primary care with a suspected lower respira-
tory tract infection (LRTI) are prescribed
antibiotics.1 However, most respiratory tract
infections are viral and only marginal beneﬁt
is achieved from the prescription of antibio-
tics that in some cases does not outweigh the
risk of harm.2–4 One of the key aims of the
UK 5-year Antimicrobial Resistance Strategy
is to conserve and steward the effectiveness
of existing treatments. Point-of-care (POC) C
reactive protein (CRP) testing for patients
with suspected LRTI has been included in
guidelines in Norway, Sweden, the
Netherlands, Germany, Switzerland, Czech
Strengths and limitations of this study
▪ Increases the understanding of the barriers to
widespread adoption of point-of-care C reactive
protein in National Health Service primary care to
guide the prescription of antibiotics for lower
respiratory tract infection.
▪ Informs the development of mitigating strategies
to overcome these barriers, including examples
of where this has been achieved in Europe.
▪ Contributes to the growing body of evidence to
support the adoption of the testing strategies
particularly given the widespread recognition of
the importance of tackling antimicrobial resist-
ance and reducing inappropriate prescribing of
antibiotics.
▪ The study included a variety of stakeholders,
allowing for an overall prospective of potential
barriers but at the expense of the sample size in
each role.
▪ The nature of the research may introduce recruit-
ment bias, as stakeholders with favourable atti-
tudes towards the test may be more likely to
accept invitations to participate.
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Republic and Estonia to determine severity of infection
and extent of inﬂammation. In the Netherlands, speciﬁc
algorithms have been developed to guide antibiotic pre-
scribing using CRP thresholds.5 Current devices allow
CRP testing to be performed from a ﬁnger-prick sample
and analysed in approximately 4 min. This strategy is
recommended by European Respiratory Guidelines.6
Several studies7–9 and a Cochrane Review4 have demon-
strated reduced antibiotic prescribing as a result.
In 2014, CRP testing was incorporated in the National
Institute of Health and Care Excellence (NICE) guide-
lines for the diagnosis of pneumonia.10 The guidelines
recommend not routinely offering antibiotic therapy if
the CRP is <20 mg/L, considering a delayed antibiotic
prescription if CRP is in the 20–100 mg/L range, and
offering antibiotic therapy if CRP concentration is
>100 mg/L. There is widespread recognition of the
importance of tackling antimicrobial resistance, and
reducing antibiotic prescribing will not only improve
antibiotic stewardship but also offer a signiﬁcant ﬁnan-
cial saving for the National Health Service (NHS); two
recent cost-effectiveness studies have demonstrated the
potential cost savings of POC CRP in the management
of LRTI.11 12
Previous qualitative studies have suggested that provid-
ing a support tool such as POC CRP to general practi-
tioners (GPs) would be received positively, and has the
ability to improve the consultation by highlighting disease
severity, manage patient’s expectations, and increase conﬁ-
dence in antibiotic prescribing.13–15 However, despite POC
CRP being routinely used in many European countries,
the test is yet to receive mainstream adoption in NHS prac-
tice. This study aimed to identify the barriers to adoption
of POC CRP testing in NHS primary care, and how similar
challenges were overcome in European countries where
POC CRP use is now widespread.
METHODS
A qualitative study was undertaken in two phases based
on grounded theory. The study description and results
are summarised in accordance with the Consolidated
Criteria for Reporting Qualitative Research (COREQ)
checklist.16 Stage 1 was a semistructured interview study
that took place in February and March 2015. Early adop-
ters in the use of POC CRP were recruited based on their
involvement in clinical trials relating to POC CRP and
identiﬁed either from our literature search or following a
recommendation by Alere International who funded the
study. Participants were recruited from both European
countries where POC CRP has already been widely
adopted, and from UK NHS practice. Convenience sam-
pling was undertaken, and potential participants were
included based on their experience in integrating POC
CRP into clinical practice. Invitations to participate in the
study were distributed by email.
The interviews were undertaken by one author ( JRH)
who is a male clinical research fellow at Imperial College
with experience in qualitative research gained through the
ongoing development of the Point-Of-Care Key Evidence
Tool (POCKET);17 there were no non-participants present
during the interviews. The interviewer did not know any of
the interview participants before the investigation, and the
participants received information on the interviewer, back-
ground and aims of the research project before the inter-
view. The interviews were semistructured, and a list of
prepared topics and questions were prepared by two
authors ( JRH and JB), piloted, and used as a prompt (see
online supplementary appendix 1). Interviews were under-
taken by telephone or Skype and recorded with no ﬁeld
notes made. Following verbatim transcription, transcripts
were not returned to participants unless clariﬁcation was
required and no repeat interviews were undertaken.
Interviews were analysed by two researchers ( JRH and
MZN, a female Senior Research Fellow at Imperial College
with a background in Decision Sciences and the applica-
tion of Decision Analysis to medicine) who independently
reviewed the transcripts using constant comparative tech-
niques before meeting to compare emergent themes.
Interviews were undertaken until saturation had been
reached, as demonstrated by the absence of new themes
emerging from analysis.
Stage 2 was a 2 h facilitated group workshop on 30
March 2015, and focused solely on the barriers to NHS
adoption. An invited multidisciplinary group of stake-
holders in the adoption of POC-in-vitro diagnostic (IVD)
were invited. Relevant stakeholder groups were identiﬁed
from the interview study and included GPs (including
those with commissioning experience), biochemists,
pharmacists, clinical laboratory scientists and industry
representatives. Convenience sampling was undertaken.
GPs were recruited through the Department of Primary
Care and Public Health at Imperial College London, and
other stakeholders directly recruited by the NIHR
Diagnostic Evidence Co-operative. All invitations were
sent by email. A maximum group size of 16 was selected
to allow for a round table discussion format. A fee was
paid to the facilitator, and an honorarium was made to
the practices of primary care participants to compensate
for their clinical time.
Two presentations preceded the workshop; the ﬁrst
outlined current evidence for POC CRP including eco-
nomic analyses, and the second presented the emergent
theme analysis from the interview study. Facilitated dis-
cussion then covered barriers to adoption, impact of
adoption and adoption scenarios. The workshop facilita-
tor was external to the research group to minimise bias
but did have expertise in the use of POC CRP. Three
members of the research group attended the workshop
including a clinician, decision analyst and member of
faculty from the Imperial College Business School who
independently reported on emergent themes from the
workshop. The workshop was also recorded and tran-
scribed for analysis in the same way as the interviews and
participants were not asked to provide further feedback
on ﬁndings.
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All interview and workshop participants had provided
informed consent to participate in the study. Qualitative
data was analysed with NVivo V.10.1.1 software (QSR
International, Melbourne, Australia).
RESULTS
Eleven experts in POC CRP were invited to participate
in the stage 1 interview study, of whom eight agreed.
Two participants declined due to lack of availability
during the study period and one participant did not
respond to the invitation. Interviews had a mean length
of 27 min (range 20–38). Four interviews were carried
out with practicing UK GPs, two of whom had an aca-
demic background. The other four interviews were
carried out with practitioners from European countries
where POC CRP is widely used, with one each from
Denmark, Norway, the Netherlands and Sweden, all of
whom were active in research.
In stage 2, 24 participants were invited to attend the
workshop of whom 10 attended; reasons for non-
attendance at the workshop were lack of availability
(10), no response from invitation (2) and acceptance of
invitation but subsequently not attending (2). The stake-
holder breakdown of workshop attendees was industry
representatives (3), GPs (2) including one with experi-
ence as a clinical commissioning group board member,
biochemist (1), clinical laboratory scientist (1), pharma-
cist (2) and primary care research manager (1). Six of
the workshop participants were men. Seven themes were
derived from the interviews and workshop transcripts
regarding the barriers to adoption of POC CRP in the
NHS: reimbursement and incentivisation, quality control
and training, laboratory services, practitioner attitudes
and experiences, effects on clinic ﬂow and workload,
use in pharmacy and gaps in evidence. The positive and
negative incentives for investing in the adoption of POC
CRP vary between stakeholder groups and mitigating
strategies are summarised in table 1.
In what follows, we present issues identiﬁed from the
interviews and workshop that would facilitate or impede
the adoption of POC CRP testing into NHS General
Practice in respect to the management of LRTI. A
summary of adoption models from the European coun-
tries where use is now mainstream is also included.
Reimbursement and incentivisation
Primary care practices cannot use the test unless it is
properly resourced. Across Europe, different reimburse-
ment structures exist with associated beneﬁts and risks.
Models from Europe include direct cost reimbursement
through insurance companies or government, govern-
ment payments for performing the test above direct test
cost, device provision by commercial laboratory services
as part of block contracts.
However, it was highlighted that some reimbursement
systems may encourage inappropriate use or overuse.
Linking reimbursement programmes to clinical
guidelines may mitigate this if payment is only made
when the test is performed according to guidelines.
Most participants see POC CRP as a cost-effective inter-
vention but concerns were highlighted that inappropri-
ate use may counteract any ﬁnancial savings.
Several procurement options were proposed throughout
the study for the NHS. These included:
▸ Direct purchase by the primary care practice;
▸ Purchase by a clinical commissioning group to cover
practices in their region;
▸ Block purchase by central government bodies (eg,
NHS England, or Public Health England) on a
national level;
▸ Purchase and ownership of devices by central labora-
tory services and loaned/leased to primary care prac-
tices (with the option of including service contracts
to cover quality assurance, maintenance and
training);
▸ Loan/lease agreements from industry (with the
option of including service contracts to cover quality
assurance, maintenance and training).
Overall, to facilitate NHS adoption, GPs will need to
be incentivised to adopt the technology. The recommen-
dation of POC CRP use in recent NICE guidelines
should be an initial facilitator for change, but the
support of other organisations is required to drive this.
In Europe, general practice colleges have led this
through the development of guidelines and algorithms
for recommended use. This may be a viable option in
the UK but it was felt that a stronger drive would be
POC CRP testing, and antimicrobial stewardship being
built into primary care quality improvement pro-
grammes and the Care Quality Commission setting out
its use as an expectation. Public health policy was previ-
ously under the remit of the primary care trusts which
were answerable to strategic health authorities. This
responsibility now rests with local authorities with
indices and metrics less aligned to clinical practice, and
therefore, a public health policy approach may require a
national intervention. The availability of test device plat-
forms that can perform other tests (eg, glycated haemo-
globin (HbA1c) or lipids) was seen as an additional
incentive (box 1).
Quality control and training
The responsibility for quality control will either belong
to primary care practitioners themselves or be out-
sourced to external bodies. European examples exist of
both local and national external quality control organi-
sations. Maintenance of devices, quality control, and an
awareness of the shelf life of test cartridges will be essen-
tial components of such a system. Devices should also
offer connectivity so that results can be uploaded to
local patient information systems.
Participants were aware of the responsibilities laid
down by the Medicines and Healthcare products
Regulatory Agency18 when adopting POC technologies
and the associated cost of quality assurance raises
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concerns. Potential mitigating strategies included service
contracts provided by industry to undertake these
responsibilities, as seen in some examples of POC being
used for health check programmes, or ownership of
quality control responsibilities being allocated to central
laboratory services that already have processes in place
to validate technologies, keep asset registers and adhere
to appropriate governance requirements.
One particular governance issue that was repeatedly
discussed was training both in performing the test and
the clinical application of results for practitioners.
Training programmes can be delivered by industry,
central laboratory services, in-house or by online video
training. Some European reimbursement schemes incorp-
orate evidence of training as a pre-requisite for reim-
bursement. Training requirements will need to be
adapted to different GP practices based on the size of the
practice and who will be performing the test. It was felt
that short refresher training would also be required,
given the possible gaps in use due to the seasonal nature
of the test (box 2).
Laboratory services
All POC CRP users from Europe and UK have good
working relationships with proactive central laboratory
services. Some participants speculated about the poten-
tial loss of income to central laboratory services, and
how this might represent a barrier to adoption of POC,
but there were no cited examples of this. Competition
with central laboratory services was therefore not
thought to be an issue. This is partly because users of
POC CRP rarely duplicated CRP testing by sending
samples to central laboratories in addition to POC
results. In addition, when POC testing is not available, it
is unlikely that a sample would be taken for central
laboratory analysis, as the result would not alter decision-
making during the consultation. Where POC CRP
testing is undertaken, it was always in partnership with
proactive central laboratory services or community POC
committees assisting with quality assurance, stocktaking,
and the monitoring of training. This collaboration also
permits the linking of results to patient electronic results
systems and to electronic patient records. There were
several examples of laboratories providing POC CRP
devices to GP practices with service contracts as part of
block service contracts. A concern with this model is
that laboratories may prefer to install POC devices in
busy inner-city practices, where they will undertake more
tests and see a faster return on their investment, disad-
vantaging rural practices (box 3). Easy access and quick
results turnover availed by the POC device is particularly
beneﬁcial when a laboratory is geographically distant or
when it is out of service (eg, out of working hours).
Practitioner attitudes and experiences
Feedback from POC CRP users was positive, with practi-
tioners reporting increased reassurance with their man-
agement plans, increased job satisfaction, and an
improvement in the ‘diagnostic pleasure’ derived from
incorporating the test result into decision-making.
However, the participants described the perception of a
‘point-of-care block’ existing in primary care. Anecdotal
examples of resistance to POC included GP colleagues
believing that extra tests, such as CRP, were not neces-
sary to make a diagnosis; that undertaking the test leads
to an unacceptable increase in duration of patient
Table 1 Summary of incentives and disincentives for POC CRP adoption by stakeholder group
Stakeholders Reasons FOR adoption
Reasons AGAINST
adoption Recommendations/next steps
NHS Early intervention by GP; less
hospital referrals; NICE pneumonia
guidelines recommendations;
evidence of reduction in
unnecessary antibiotics prescription
when CRP test results are used
Funding mechanism needs to
balance encouraging
adoption of POC CRP and
overuse
Clear POC CRP user guideline
necessary
General
Practitioners
Increased diagnostic confidence;
increased decision-making support
especially when in doubt; improved
communication with patients;
improved access to test that
overcomes geographical distance;
early adopters/opinion leaders
continue to publish evidence that
favours wider-scale adoption
Behaviour inertia and risk
aversions; perception of the
test taking up too much time;
POC CRP expensive to take
up
Perception of time can be corrected
—successful adoption model exists;
further evidence required on clinical
utility at individual GP practice
Laboratories Active role in quality control,
training, maintenance of POC
devices that are consistent with the
future of laboratory services
Income loss due to not
performing CRP tests, but
the impact presumably small
Funding route carefully managed to
encourage and ensure quality
maintenance role by clinical
laboratories
CRP, C reactive protein; GP, general practitioner; NHS, National Health Service; NICE, National Institute of Health and Care Excellence;
POC, point-of-care.
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consultation; and concerns about the sensitivity of the
test and the appropriate way to manage an unexpected
or misleading rise in CRP when the clinical ﬁndings do
not correlate.
Many GPs regard the test as an adjunct to their com-
munication when educating patients in antimicrobial
stewardship. However, one GP raised concerns that
increased reliance on diagnostic tests may restrict the
holistic approach that is fundamental to primary care
patient interactions, and psychosocial aspects of a
patient’s presentation may be missed. The participants
who had experience in POC CRP use all highlighted
positive reactions from patients in relation to the test.
One GP simply answered ‘They love it’. No cultural bar-
riers were identiﬁed in the study, although there were
concerns that the popularity of the test may predispose
to overuse both arranging GP consultations with minor
symptoms to beneﬁt from the ‘reassurance’ of a normal
CRP, or sequential testing following a normal or border-
line result if symptoms were not resolving (box 4).
Effects on clinic flow and workload
Three participants discussed their impression of the
impact of POC CRP testing on clinic ﬂow. One
described no effect, one described a change in ﬂow with
no overall consequence, and the ﬁnal one observed that
there is an effect but a robust process for testing can
mitigate this. GP workload is currently at capacity,19 and
any perceived effects on clinic ﬂow, additional workload,
or increasing patient consultations may inhibit adoption
of the test. However, the impact on workload will
depend on the approaches to testing adopted by speciﬁc
GP practices. Some examples were given of the test
being undertaken by the GP within the consultation,
others included the patient leaving the consultation to
have the test being undertaken by a practice nurse,
healthcare assistant, or inhouse primary care laboratory
technician, while the practitioner sees the next patient;
Box 1 Direct quotations from participants relating to
reimbursement and incentivisation
“Getting the reimbursement formula right is important…it
shouldn’t just be, I think, use it every time you like and you’ll get
paid for it…but primary care can’t do it unless it’s properly
resourced.” (Interview participant 6)
“The costs would need to be reimbursed in some format, and it
would need to be part of a quality improvement programme for
general practice.” (Interview participant 5)
“It’s widely used in Scandinavian countries because the clinicians
get basically a payment each time they use the test.” (Interview
participant 6)
“The problem is, if you paid them [GPs] every time they use it,
then they’re going to use it when they don’t really need to be
using it.” (Interview participant 6)
“Some sort of quality standard that includes CRP testing within a
fairly rigid protocol, which is able to be audited and reported
might be a beneficial process, although it would need to be not
open to abuse.” (Interview participant 5)
“The CCG would need to make a decision…we’re going to put
these machines in every practise and pay for them…I’m quite
certain that GPs wouldn’t just do this out of their own pockets
because that’s just not the way it works.” (Interview participant 4)
“The engagement needs organisations, such as NHS England and
CQC…making directives that practices have got to have this
equipment by such and such a date, CQC, in their regulatory role,
making sure that things are put in place, and making it known in
the annual cycles of change, that this is the sort of thing they’re
looking for, so that come this time next year, practices have got
this in place.” (Workshop participant)
“To get people, particularly in terms of path finding, or innovating,
or piloting different areas, you tend to have to incentivise them.”
(Workshop participant)
“Maybe general practitioners will be told they have to finance it
themselves from their income, but again, that would need CQC to
have the support of NICE, to say this is an essential expectation
of all general practise and all primary care.” (Workshop
participant)
Box 2 Direct quotations from participants relating to
Quality Control and Training
“I want to make a strong plea for quality assurance, and that GPs
should prove that they attach to such a programme.” (Interview
participant 2)
“If this could be devolved with the CCG, whereby the CCG can
have an asset list, it removes some of the red tape, from a GP
perspective.” (Workshop participant)
“The lab [central laboratory services] would be able to help with
that…we already have existing systems in place to meet the
MHRA standard, the CQC standard for point of care…we already
have an asset register…so all those governance issues, you won’t
have any problem with that.”
“I think this is going to be part and parcel of the whole process
of accreditation, quality assurance, incentivisation, training,
audits, it’s all part of quality control.” (Interview participant 5)
“Respiratory tract infections being seasonal, one could imagine a
long period of time when the equipment is not used…what are
the risks of inaccuracy with equipment when one is not familiar
with using it.” (Workshop participant)
“Any training packages have got to have different modalities
between face-to-face group training, videos, refresher videos,
video manuals, or things which can be quite short as refreshers,
maybe just a minute or two for the slightly overworked and
oppressed clinician trying to make a decision on a patient late at
night, as opposed to the novice using it for the first time.”
(Workshop participant)
Box 3 Direct quotations from participants relating to
Laboratory Services
“What helps the implementation is the fact that we’ve got a dedi-
cated point-of-care team central laboratory and the chemistry
laboratory who will come out, plug in and teach the standard
operating procedures.” (Interview participant 8)
“Perhaps that is where the pathology department can help
support the GP. You say you can’t do technical evaluation in the
patient group that you will actually will get…we do that routinely
within the hospital.” (Workshop participant)
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decision-making would then follow based on written
instructions from the practitioner, or a second consult-
ation being undertaken. These options are summarised
in ﬁgure 1 (box 5).
Use in pharmacy
Many patients with symptoms of LRTI do not present to
their GP. Community pharmacies were highlighted as a
potential alternative setting for POC CRP. As with
primary care surgeries, this would need appropriate
incentivisation, particularly as pharmacists may lose
income if antibiotic prescribing is reduced. NHS initia-
tives are encouraging pharmacist independent prescri-
bers in certain areas such as hypertension and
respiratory illness,20 21 and it was suggested that anti-
biotic prescribing for LRTI, guided by a POC CRP-based
algorithm, could be evaluated for inclusion in future
policies. Some concern was raised that this may dupli-
cate work, as patients may arrange a GP visit in addition
to pharmacist consultation, and a signiﬁcant culture
change may be required to negate this (box 6).
Where further evidence is required
The evidence for POC CRP is summarised in the intro-
duction. However, gaps raised during the interview study
included the need for an implementation study to inves-
tigate overall patient and societal outcomes and alterna-
tive indications for POC CRP in primary care. Workshop
participants also sought further evidence on the risks of
not prescribing based on POC CRP and guidance in the
application of test results to different populations,
including children and patients with comorbidity (such
as rheumatoid arthritis and chronic obstructive pulmon-
ary disease).
Adoption models in Europe
Successful adoption models in the European countries
where we interviewed experts showed a distinct pattern.
That is, a slow and long early adoption phase followed
by policy changes that then triggered large-scale adop-
tion. In countries where the device is widely used, a few
opinion leaders became early adopters, recognising the
importance of using the device to support their
decision-making in antibiotics prescriptions. Through
clinical practice and research, these early adopters con-
tinued to generate and publish evidence. Eventually, the
national professional bodies became advocates of the
new technology. The accumulation of evidence and
support from the practitioners, especially when
Box 4 Direct quotations from participants relating to
Practitioner attitudes and experiences
“Changing clinician behaviour is a slow process and there’s an
organic and a cultural process.” (Workshop participant)
“Instinctively, GPs feel that they don’t need a lot of tests to make
a diagnosis.” (Interview participant 4)
“It’s almost like…they [GPs] feel that the machine will make the
decision on behalf of them…it deprives them of the decision
making capability, the learning opportunity.” (Workshop
participant)
“Anything that prolongs the consultation will be seen as a
problem.” (Interview participant 4)
“GPs are very satisfied by having an instrument in the consulta-
tions that can help them to make the right decision.” (Interview
participant 3)
“If we set up a facility, which offers near patient testing, numeri-
cising an illness, or a future of an illness, there’s a risk we
become very much transactional doctors…and we’ve always
prided ourselves in primary care that we maybe discriminate
some of the psychosocial symptoms and de-medicate our
patients better that our secondary care colleagues. I’m not saying
that that outweighs the benefits at all, but I think it needs to be
taken into account.” (Workshop participant)
“It’s quite useful when they say they might feel the person
doesn’t need antibiotics but the patients are keen for the antibio-
tics. Then it’s an adjunct to the communication skills.” (Interview
participant 6)
“May be that people want to come back because they love the test
so much.” (Interview participant 4)
“They’ve got CRP of about 20, 18 or something like that. But two
days later, they’re not very well, so they’ll want another CRP…
this is opening a potential can of worms.” (Workshop participant)
“Reassurance can be a very powerful tool.” (Interview participant 4)
“I think it increases the trust in the GP.” (Interview participant 1)
“Nowadays patients, if they have a sore throat or they have catarrh
they may think I have to go to the doctor not to get antibiotics
but to have the test.” (Interview participant 3)
Box 5 Direct quotations from participants relating to
Effects on clinic flow and workload
“It will have an effect, but if you have the healthcare assistant do
the test, while you see another patient, it shouldn’t make too
much difference.” (Interview participant 6)
“I think most doctors will see another patient in between and
return to the first patient afterwards.” (Interview participant 2)
“I think we’ve got barriers of the workload, and the workload in
clinical practise is very heavy at the moment. It’s, sort of, recog-
nised on a national level. And capacity comes indifferent areas,
not just the capacity of workload, it’s the capacity and space.”
(Workshop participant)
“Once patients say ‘that was a really good test doctor…I want the
test’…they are entitled to the service. Now, they don’t want the
antibiotics, they want the test. It’s about managing demand.
Unfortunately, even with infinite capacity, I promise you, where
cost is free, you’d have infinite demands as well.” (Workshop
participant)
“If it’s an infinite resource, you could argue that you could do this
point of care testing on everyone who presents with a cold.
Where do you draw the line?” (Workshop participant)
“There are clear-cut cases you think we should prescribe [antibio-
tics]. Maybe it’s the middle area that you find it hard to convey to
patients…and you have that additional thing to help to convince,
actually, that it’s a good idea not to give antibiotics.” (Workshop
participant)
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embedded in a policy environment that encouraged the
use of POC technology and a government drive to
reduce over-prescription of antibiotics, laid the founda-
tion for a resource allocation model that supported
large-scale adoption. However, the process was regarded
as slow, ranging from 2 to 7 years between initial adop-
tion by opinion leaders and the eventual large-scale
implementation.
DISCUSSION
Summary of main findings
This qualitative study found a number of barriers that
stand in the way to the mainstream adoption of POC
CRP testing into NHS primary care for the management
of LRTI. These challenges have been mitigated in other
European counties where the test is more widely used,
and lessons can be learnt from their practice. Many strat-
egies could be directly transferred to UK practice and
scaled-up to promote NHS implementation. The
primary barrier at present is the absence of a UK
funding and reimbursement model for the test. Several
funding models were proposed during the study, each
with their own incentives for reimbursement, but there
is a risk that inappropriate schemes may lead to overuse
or underuse of the test potentially leading to an overall
reduction in cost-effectiveness.
There were concerns raised by practitioners regarding
the burdens associated with maintenance, stocking and
quality assurance of the test device and cartridges. It
may be that as seen in Europe, laboratories can play a
role in the process with resource allocation models to
support laboratories to actively take part in primary care
POC testing with service agreements to act as test admin-
istrators, quality controllers and trainers.
Implementation of POC CRP will require changes to
working practices and clinic ﬂow. The time and human
resources required to undertake testing will need to be
absorbed into already stretched clinics. Examples of how
this has been achieved were included, but individual
practices and practitioners will need to consider their
own stafﬁng, infrastructure and culture when establishing
a testing service. While the study investigated the use in
primary care, alternative models were proposed includ-
ing use of the test in pharmacy. The increasing use of
pharmacist prescribers will make this feasible, and many
pharmacists are keen to offer such enhanced services.
Strengths and limitations
This study does have several limitations. From the
sample size we have, we may not have presented a com-
prehensive overview of POC CRP use and adoption
across all of Europe. Instead, we aimed to select partici-
pants with academic backgrounds who were involved in
the early stages of adoption in their respective countries
to learn from their success. Second, as with all qualita-
tive research, study participation involves a time burden
to undergo interviews and attend workshops. Therefore,
the study is prone to recruitment bias, as those with posi-
tive attitudes towards the test may have been more likely
to attend, and there were many invited participants who
choose not to participate, although data collected and
presented includes positive and negative beliefs regard-
ing the test. Every attempt was made to recruit a repre-
sentative sample of stakeholders, but convenience
sampling was unavoidable. We believe we have included
a wide range of stakeholders with differing interests in
the test use, and that the highlighted themes are of
importance and relevance within the NHS as a whole.
However, a tradeoff for including this variety of
Box 6 Direct quotations from participants relating to
where further evidence is required
“We need the evidence, we need the evidence across all areas,
not just antibiotic resistance, but…in terms of clinical outcomes,
that this is an effective tool in delivering improved healthcare.”
(Workshop participant)
“I think that’s the kind of space for implementation study that
might still be needed.” (Interview participant 6)
Figure 1 Flow diagram of
typical patient pathway
incorporating point-of-care CRP
testing. CRP, C reactive protein;
GP, general practitioner.
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stakeholders was that the sample size in each role was
reduced. In particular, only two GPs attended the work-
shop, and although previous research has been under-
taken to investigate the attitudes of this group a larger
sample of GPs would have beneﬁtted this study. As
included stakeholders were experts in the use of POC
CRP, patients were not included in this study. Therefore,
the reporting of patient attitudes was anecdotal and
needs validation.
We used a workshop facilitator who was independent
to the research group and a series of open-ended ques-
tions to minimise any bias resulting from the prior
beliefs of the group. The researchers undertaking the
coding were not from a primary care background but
did have a clear understanding of the clinical pathway
and included expertise in medical decision-making. By
not sharing the professional background of the partici-
pants, there may be restrictions in the depth of explor-
ation undertaken, but it was felt that the coders
background meant they were less likely to have their
own beliefs inﬂuence the study results, and coding was
undertaken independently without a requirement for
consensus. Finally, peer debrieﬁng was not undertaken,
although there was scope within the methodology to
clarify any aspect of the collected data if it were to have
been required.
Comparison with existing literature
A previous systematic review of primary care practitioner
attitudes to the use of POC tests highlighted concerns
about accuracy, misleading results, over-reliance and the
cost of equipment and maintenance and tests not being
helpful in altering consultations.22 While many of the
same apprehensions were discussed in the current study,
most were not seen as barriers. Accuracy was discussed, but
this was in respect to distinct patient groups, such as chil-
dren or patients with comorbidities, where further evi-
dence is required, and current POC CRP devices have
been shown to perform with similar accuracy to laboratory
analysers.23 The cost of the test was highlighted in respect
to the need for a suitable reimbursement model, but the
overall cost-effectiveness of test adoption was felt to be a
facilitator. One focus group participant did raise the
subject of over-reliance, and the risk of transforming the
consultation into a paper exercise, potentially detracting
from the holistic approach to what is often complex multi-
factorial patient care. However, a caveat was provided that
the beneﬁts of reducing antibiotic prescribing may out-
weigh these concerns, and when the test is used appropri-
ately, the extra information provided should improve the
quality of consultations both in respect to the doctor–
patient relationship and the end management.
Overall practitioner attitudes towards the adoption of
POC CRP were encouraging. The perceived beneﬁts in
antibiotic prescribing and communication were forth-
coming, and of those stakeholders already using the test
in clinical practice, patients’ responses were perceived to
be positive. This coincides with a recent survey study
that demonstrated that 61% of UK GPs would welcome
access to POC CRP in their clinic,24 and studies have
repeatedly demonstrated a high rate of patient accept-
ability towards POC testing strategies.6 14 25
Implications for practice
Many barriers discussed in this paper are perceived
and can be overcome with relatively minor changes to
work patterns, culture and education. However, struc-
tural barriers including the lack of funding model and
reimbursement strategy will require policy change if
widespread NHS adoption is to be achieved. Within
the UK, POC CRP has been recommended in the
NICE pneumonia guidelines. Using CRP testing is also
consistent with the government drive to reduce anti-
microbial resistance. Given that GP practices may be
initially unwilling to fund the device themselves, a suc-
cessful funding mechanism that would lead to
large-scale adoption would (1) facilitate take-up and
implementation into mainstream practice, (2) discour-
age device misuse and (3) encourage active role transi-
tion played by the clinical laboratory. It is essential
that clear guidelines exist to govern how and when
POC CRP testing should be used, and establishing
antimicrobial stewardship into quality improvement
frameworks may achieve this.
In conclusion, many GPs would welcome POC CRP as
an additional tool for their diagnostic armoury.
Disincentives and incentives exist for all stakeholders,
but mitigating strategies exist. Further research should
be aimed at investigating the impact of scaling-up NHS
implementation at a patient practice and wider health
system level. Use of the test in children and those with
comorbidities should also be investigated. Particular
focus needs to assess the economic impact of test adop-
tion in primary care to ensure the cost-effectiveness
described in previous reports7 8 holds true in real-world
adoption.
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